中国药业2013，Vol.22Issue(12)：9-12,4.
凝血酶抑制剂的研究进展
Research Progress on Thrombin Inhibitor
周莹 1何志龙 2孔毅2
作者信息
- 1. 浙江省杭州市中医院,浙江杭州 310007
- 2. 中国药科大学生命科学与技术学院,江苏南京 210009
- 折叠
摘要
Abstract
Arterial and venous thrombosis are major causes of morbidity and mortality and,with an aging population,their incidence will increase further.Although currently available anticoagulants are effective for the prevention and treatment of thromboembolic diseases,they have their own drawbacks.Low molecular weight heparin and fondaparinux produce a predictable level of anticoagulation without needing the coagulation monitoring,but they must be given by injection,which renders them inconvenient for long-term use.Warfarin as one of vitamin K antagonists by oral administration produces variable anticoagulant responses due to genetic polymorphisms,dietary vitamin K intake and multiple drug-drug interactions for affecting its metabolism.Consequently,coagulation monitoring and frequent dose adjustments are needed to ensure that a therapeutic level of anticoagulation is achieved.For these reasons,the new oral anticoagulants with thrombin or factor X as the target have become the development hot spot.关键词
血栓性疾病/抗凝血药/凝血酶抑制剂Key words
thrombotic diseases/ anticoagulants/ thrombin inhibitors分类
医药卫生引用本文复制引用
周莹,何志龙,孔毅..凝血酶抑制剂的研究进展[J].中国药业,2013,22(12):9-12,4.
